85

Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort study

Mats Steinholtz Ahlberg , Hans Garmo , Hans-Olov Adami , Ove Andrén , Jan-Erik Johansson , Gunnar Steineck , Lars Holmberg , Anna Bill-Axelson

BMJ Open

SPCG-4

Abstract

84

Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)

Andreas Josefsson, Åsa Jellvert, Erik Holmberg, Klaus Brasso, Peter Meidahl Petersen, Sirpa Aaltomaa, Marjaana Luukkaa, Paul Verhagen, Ronald de Wit, Göran Ahlgren, Ove Andrén, Enrique Castellanos, Mihalj Seke, Anders Widmark, Jan-Erik Damber & the SPCG14-investigators

ACTA ONCOLOGICA 2023, VOL. 62, NO. 4, 372–380

SPCG-14 (SPCG-14 PSA-ERECT M0)

Abstract

83

Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study

MIIKKA LEHTONEN, JORMA SORMUNEN, MARIE HJÄLM-ERIKSSON, CAMILLA THELLENBERG-KARLSSON, TEPPO HUTTUNEN, CLAES GINMAN and PIRKKO-LIISA KELLOKUMPU-LEHTINEN

ANTICANCER RESEARCH 42: 87-92 (2022)

SPCG-13

Abstract

82

Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study

Lehtonen M, Sormunen J, Hjälm-Eriksson M, Thellenberg-Karlsson C, Huttunen T, Ginman C, Kellokumpu-Lehtinen PL; Investigators of the Scandinavian Prostate Cancer Group Study No 13.

Anticancer Res. 2022 Jan

SPCG-13

Abstract

81

Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial

Bjørg Y Aksnessæther, Tor Åge Myklebust, Arne Solberg, Olbjørn H Klepp, Eva Skovlund, Solveig Roth Hoff, Sophie D Fosså, Anders Widmark, Jo-Åsmund Lund

J Radiat Oncol Biol Phys

Abstract

80

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Lennart Åström, Lars Franzen, Ann-Sofie Fransson, Markku J Leskinen, Mihalj Zeke, Teppo Huttunen, Claes Ginman, Investigators of the Scandinavian Prostate Cancer Study No. 13

Eur Urol

Abstract

79

PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design

Mats Steinholtz Ahlberg, Hans-Olov Adami, Kerri Beckmann, Helena Bertilsson, Ola Bratt, Declan Cahill, Lars Egevad, Hans Garmo, Lars Holmberg, Eva Johansson, Antti Rannikko, Mieke Van Hemelrijck, Fredrik Jäderling, Cecilia Wassberg, Ulrika W N Åberg, Anna Bill-Axelson

BMJ Open

SPCG-17

Abstract

78

Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W.

Radiother Oncol. 2019

Abstract

77

Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.

Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P.

BJU Int. 2019

SPCG-4

Abstract

76

Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up

Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Andrén O, Steineck G, Adami HO, Johansson JE.

N Engl J Med. 2018

Abstract